| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/10/2013 | EP2578571A1 Isoquinoline modulators of ATP-binding cassette transporters |
| 04/10/2013 | EP2578570A1 Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
| 04/10/2013 | EP2578569A1 Heterocyclic ring compound and h1 receptor antagonist |
| 04/10/2013 | EP2578236A1 PREPARATION OF MICROVESICLE-siRNA COMPLEXES AND USE THEREOF IN AIDS TREATMENT |
| 04/10/2013 | EP2578233A1 Therapeutic agent for pancreatic cancer |
| 04/10/2013 | EP2578231A1 Antitumor t cell response enhancer |
| 04/10/2013 | EP2578220A1 Influenza virus infection inhibitor |
| 04/10/2013 | EP2578219A1 Novel indazole derivative or salt thereof, manufacturing intermediate therefor, antioxidant using same, and use for an indazole derivative or salt thereof |
| 04/10/2013 | EP2578218A1 Antiviral efficacy of disodium 2,6-dimethyl-1,4-dihydropyridine-3,5-bis(carbonyloxyacetate) and its derivatives |
| 04/10/2013 | EP2578217A1 Sympatholytic agent, and cosmetic, food and sundry containing same |
| 04/10/2013 | EP2578216A1 Methods of treating fragile x syndrome |
| 04/10/2013 | EP2578215A1 Use of oxaloacetate in the treatment of ischaemia |
| 04/10/2013 | EP2578214A2 Pharmaceutical composition for the prevention or treatment of inflammatory diseases or immune diseases containing ramalin |
| 04/10/2013 | EP2578213A1 Treatment of oral pharyngeal dysphagia |
| 04/10/2013 | EP2578212A1 Compound inhibiting activation of the enzyme erk1/2 for use in the treatment of neurogenerative illnesses |
| 04/10/2013 | EP2578211A1 6-decaprenyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone-based composition and method for the production thereof |
| 04/10/2013 | EP2578210A1 Rottlerin for the treatment of pulmonary hypertension and related diseases and disorders |
| 04/10/2013 | EP2578209A1 Nanoparticulate composition containing antibiotics for intramammary administration in animals |
| 04/10/2013 | EP2578206A1 Pharmaceutical composition for the treatment of disorders of the lower section of the urogenital system |
| 04/10/2013 | EP2578186A2 Drug-delivery endovascular stent and method for treating restenosis |
| 04/10/2013 | EP2578087A1 Pet food |
| 04/10/2013 | EP2576813A1 Procedure for biphasic preparation of liposomes and application thereof in manufacturing diagnostic reagents |
| 04/10/2013 | EP2576786A1 High-affinity nucleic acid aptamers against sclerostin protein |
| 04/10/2013 | EP2576785A2 Regulation of metabolism by mir-378 |
| 04/10/2013 | EP2576784A2 Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra |
| 04/10/2013 | EP2576783A2 Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 |
| 04/10/2013 | EP2576782A1 Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| 04/10/2013 | EP2576781A2 Composition and method for inner ear sensory hair cell regeneration and replacement |
| 04/10/2013 | EP2576699A1 Naphthocyanines for use as contrast agents |
| 04/10/2013 | EP2576586A1 C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors |
| 04/10/2013 | EP2576585A1 Modified c-3 betulinic acid derivatives as hiv maturation inhibitors |
| 04/10/2013 | EP2576582A1 Treatment of muscular dystrophy |
| 04/10/2013 | EP2576579A2 Compositions and methods directed to treating liver fibrosis |
| 04/10/2013 | EP2576578A1 Polymorphs of 2'-o-fucosyllactose and producing thereof |
| 04/10/2013 | EP2576576A1 Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
| 04/10/2013 | EP2576575A1 Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof |
| 04/10/2013 | EP2576568A1 An aminopyrazole triazolothiadiazole inhibitor of c-met protein kinase |
| 04/10/2013 | EP2576567A1 Nitroimidazole derivatives |
| 04/10/2013 | EP2576566A1 Thieno (2, 3b) pyrazine compounds as b - raf inhibitors |
| 04/10/2013 | EP2576564A2 Macrocyclic hepatitis c serine protease inhibitors |
| 04/10/2013 | EP2576562A1 Processes for the preparation of dipyridamole |
| 04/10/2013 | EP2576561A1 Heterocyclic compounds as janus kinase inhibitors |
| 04/10/2013 | EP2576560A1 Substituted imidazopyrazines |
| 04/10/2013 | EP2576559A1 Inhibitors of jnk |
| 04/10/2013 | EP2576557A1 NOVEL ANTIFUNGAL 5,6-DIHYDRO-4-[(DIFLUOROETHYL)PHENYL]-4H-PYRROLO[1,2-a][1,4]BENZODIAZEPINE AND 4-(DIFLUOROETHYL)PHENYL-6H-PYRROLO[1,2-a][1,4]BENZODIAZEPINE DERIVATIVES |
| 04/10/2013 | EP2576552A2 Benzoquinolone inhibitors of vmat2 |
| 04/10/2013 | EP2576549A2 Bicyclic heteroaryl kinase inhibitors and methods of use |
| 04/10/2013 | EP2576548A1 THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc). |
| 04/10/2013 | EP2576547A1 Substituted 5-fluoro-1h-pyrazolopyridines and use thereof |
| 04/10/2013 | EP2576546A1 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| 04/10/2013 | EP2576545A1 Nitrate and diazeniumdiolate derivatives of pioglitazone |
| 04/10/2013 | EP2576544A2 Cytochrome p450 inhibitors and uses thereof |
| 04/10/2013 | EP2576543A1 Pyrazole compounds as sigma receptor inhibitors |
| 04/10/2013 | EP2576542A1 Ccr2 receptor antagonists |
| 04/10/2013 | EP2576541A1 Aminopyrimidine derivatives as lrrk2 modulators |
| 04/10/2013 | EP2576540A2 Heteroaryl compounds and methods of use thereof |
| 04/10/2013 | EP2576538A1 New ccr2 antagonists |
| 04/10/2013 | EP2576537A1 2 -amino- pyrimidine derivatives useful as inhibitors of jnk |
| 04/10/2013 | EP2576535A1 Combination cancer therapies with wortmannin analogs |
| 04/10/2013 | EP2576534A1 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
| 04/10/2013 | EP2576532A1 Furanyl compounds and the use thereof |
| 04/10/2013 | EP2576520A1 Radiolabeled compounds and methods thereof |
| 04/10/2013 | EP2576514A1 Substituted isoquinolines and their use as tubulin polymerization inhibitors |
| 04/10/2013 | EP2576513A1 Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases |
| 04/10/2013 | EP2576510A1 Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer |
| 04/10/2013 | EP2576509A1 Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies |
| 04/10/2013 | EP2576507A1 Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application |
| 04/10/2013 | EP2576505A1 Process for the preparation of pleuromutilins |
| 04/10/2013 | EP2576496A1 Nicotinic receptor non-competitive antagonists |
| 04/10/2013 | EP2575993A1 Process for extracting materials from biological material |
| 04/10/2013 | EP2575969A1 Antiviral activity of novel bicyclic heterocycles |
| 04/10/2013 | EP2575968A1 Compounds for the treatment of clostridium difficile associated disease |
| 04/10/2013 | EP2575909A1 Malleable hydrogel hybrids made of self-assembled peptides and biocompatible polymers and uses thereof |
| 04/10/2013 | EP2575893A1 Conjugates for the prevention or treatment of nicotine addiction |
| 04/10/2013 | EP2575892A1 2-iminobiotin formulations and uses thereof |
| 04/10/2013 | EP2575889A2 Stable pharmaceutical compositions of rapamycin esters |
| 04/10/2013 | EP2575883A2 Treatment of inflammatory disorders |
| 04/10/2013 | EP2575876A1 Multivalent synthetic nanocarrier vaccines |
| 04/10/2013 | EP2575861A1 A novel synergistic pharmaceutical composition for topical applications |
| 04/10/2013 | EP2575854A1 Cyclosporin emulsions |
| 04/10/2013 | EP2575841A2 Apple skin extracts for treating cardiovascular disease |
| 04/10/2013 | EP2575839A2 Oral formulations for counteracting effects of aging |
| 04/10/2013 | EP2575829A1 Kit for the treatment of onychomycosis by nitric oxide |
| 04/10/2013 | EP2575827A2 Urea sorbent |
| 04/10/2013 | EP2575826A1 Anti-diabetic compositions and methods |
| 04/10/2013 | EP2575825A2 Compositions and methods for treating depression |
| 04/10/2013 | EP2575824A2 Methods for the treatment and prevention of inflammatory diseases |
| 04/10/2013 | EP2575823A1 3-substituted vinylboronates and uses thereof |
| 04/10/2013 | EP2575822A2 Topical pharmaceutical compositions comprising mometasone furoate |
| 04/10/2013 | EP2575821A2 Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| 04/10/2013 | EP2575820A1 Controlled release dosage form comprising quetiapine |
| 04/10/2013 | EP2575819A1 Hepatitis c virus inhibitors |
| 04/10/2013 | EP2575818A2 The use of inhibitors of bruton's tyrosine kinase (btk) |
| 04/10/2013 | EP2575817A1 Organic compounds |
| 04/10/2013 | EP2575816A1 Combination therapy for skin disorders |
| 04/10/2013 | EP2575815A1 Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
| 04/10/2013 | EP2575814A1 Pharmaceutical compositions and administrations thereof |
| 04/10/2013 | EP2575813A1 Topical etoricoxib formulation |
| 04/10/2013 | EP2575812A2 Pharmaceutical composition comprising cefpodoxime proxetil and clavulanic acid |
| 04/10/2013 | EP2575811A1 Pharmaceutical formulation comprising cefpodoxime proxetil and clavulanic acid |